Anthem biosmi biosmi Bioscionces IPO Day 2: 1,21 Application to date; Should you apply?

Initial public stockings (IPO) of Anthem Biological congestion into its second date on Tuesday. At 10:57 AM, IPO applied for 1.21 times, supporting all 5.70,70,72 shares to BSE.

The buyer of the institution (QBBBS) was offered for 47,4,996 shares resistance to 1,25,43,518 shares in offer. Meanwhile, non-institutional types of (NIIS) continues to express their strong interest ,,99,81,818 shares per 94,079 shares.

Personal retail sales (Riis) showed moderate involvement, by 2,19,450 shares resisted by 0.92 shares.

The IPO BIDDED windows will close on Wednesday July 16 July 16 July.

Anthem Biological: Apply Date 1

On the first day of auction, the issue was subscribed 0.73 times, with investors place 0.73 times. Before the IPO opens, the company is classified by 1,78 shares to the 60 Ergor investor at 570, which is the ipo level.

Anthem Biological: Should You Apply? This is what anil Singhvi suggested

Zee editor Zee Managing Anil Singhvi gave positive views in IPO. You suggested investors apply both the list of both benefits and shares for 2-3 years as long-term investments. “Apply good and long-term income. This stock should be in your Pharma Portfolio for 2-3 years,” he said.

Also read:Biosmerm BiosCiedences Increases 1.016 crore from the anchor investor before IPO

What works in the favor of the company:

• Experienced and professional advertiser
• Market leaders in Cldmo (contract and production research)
• Follow the record of a successful drug
• Long-term relationship with customers
• Strong financial, positive cash flow, and a very low debt
• Better finances compared to the listing competitors
• While smaller than divi laboratory in size, it matches the quality

Risks and concerns:

• Heavy dependency of one client (Davos Harmarman contributed 14 percent of the income)
• R & D spending fell
• Growing depending on the success of a new drug molecule
• The value assessment is fair – no cheap too, not too expensive

Openm Bioiom Description

IPO This is an offer for sale (of), means that the money raised will go to promote and investors available. The price band has been set to Rs 540 to 570 rupees per share. Investors can apply for more than 26 shares and in the coefficient of that.

In finance, the company has earned 30 percent from Rs 1.419 crore in FY24 to 1,844 crore in FY25. The net profit also increases for 23 percent to 451 rs CRORE.

Industrial competitors

Anthem biome operates in an area of Anthem and Biotech. Friendship with its list include Sairy Life Science, Syngene International, Seven Life, Divi scientity, and divi laboratory.